Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
141-160 of 2,251 trials

Rheumatoid Arthritis: Precision Therapy Using Biomarkers

We are studying if tissue samples can help identify which RA patients will respond best to new biologic treatments. This may improve treatment outcomes for those who haven't benefited from standard therapies.

Rheumatoid ArthritisMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesRheumatology

Nuwiq for Managing Bleeding in Hemophilia A Patients During Surgery

We are studying how well Nuwiq works alongside emicizumab for patients with severe hemophilia A undergoing major surgery. The goal is to see if it helps control bleeding effectively and safely.

Haemophilia AMonitoring phase (IV)No PlaceboStandard MedicinesHematology

Nuwiq for Women and Girls with Hemophilia A Needing Surgery

We are studying how well Nuwiq works to control bleeding during major surgery for women and girls with hemophilia A. The trial will also look at its safety and effects on blood product use.

Haemophilia A≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyInternal Medicine

Zilucoplan for Children with Generalized Myasthenia Gravis

We are studying the long-term safety of zilucoplan in children with generalized myasthenia gravis who participated in an earlier trial. This research aims to understand how well the treatment works and its effects over time.

Myasthenia GravisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Myasthenia Gravis: Rozanolixizumab for Kids

We are studying if rozanolixizumab is safe and effective for children with moderate to severe myasthenia gravis. This trial will help us understand how the medication works in young patients.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNeurologyPediatrics

Osteoporosis: Dasatinib and Quercetin Study

We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.

OsteoporosisOsteopenia3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Small Cell Lung Cancer: Niraparib with Immunotherapy

We are studying the effects of adding niraparib to immunotherapy for patients with SLFN11-positive small cell lung cancer. This research aims to see if it improves treatment after initial therapy.

Extensive Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Pancreatic Cancer: Short vs. Long Chemotherapy

We are comparing two lengths of chemotherapy before surgery for patients with borderline and locally advanced pancreatic cancer. Our goal is to find out which duration may help improve survival rates.

Advanced Pancreatic Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyOncology

Atrial Fibrillation: WOEST-3 Study

We are exploring a new antithrombotic strategy for patients with atrial fibrillation undergoing heart procedures. The goal is to see if this approach reduces bleeding and heart-related risks compared to standard treatment.

Atrial FibrillationAcute Coronary SyndromeChronic Coronary Syndrome1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Neuroendocrine Tumors: 177Lu-edotreotide vs. Everolimus

We are studying whether a new treatment, 177Lu-edotreotide, can help patients with neuroendocrine tumors of the lung and thymus live longer without disease progression compared to everolimus.

Neuroendocrine Tumor>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Chronic Graft-Versus-Host Disease: Axatilimab and Ruxolitinib Study

We are studying a new treatment combining axatilimab and ruxolitinib for people newly diagnosed with chronic graft-versus-host disease. The goal is to see if this combination is safe and effective in improving their condition.

Chronic Graft-Versus-Host Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementAllergologyHematologyInternal Medicine

Achondroplasia: TransCon CNP Treatment

We are studying a new weekly injection for children and adolescents with achondroplasia to see if it is safe and helps improve growth. This trial will help us understand the long-term effects of this treatment.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Bladder Cancer Treatment: Chemoablation vs. Standard Care

We are studying whether a new chemoablation method is more effective than standard bladder surgery and chemotherapy for patients with recurrent non-muscle invasive bladder cancer. This may help reduce recurrence rates and improve long-term outcomes.

Recurrent Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

HPV Vaccine Effectiveness Study for Young Men

We are studying how well the bivalent HPV vaccine protects men aged 19-26 who have sex with men from anal HPV-16/18 infections. This research aims to understand vaccination impact and related factors.

HPV InfectionHealthy Participants6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Hodgkin Lymphoma: Tislelizumab with Gemcitabine and Cisplatin

We are studying a combination of tislelizumab, gemcitabine, and cisplatin for patients with relapsed or refractory Hodgkin lymphoma. The goal is to see if this treatment improves survival and response rates.

Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Ventilator-Acquired Pneumonia: Interferon Gamma Treatment

We are studying whether recombinant human interferon gamma can help ICU patients with ventilator-acquired pneumonia breathe easier and recover faster. This trial looks at its effects alongside standard antibiotic treatment.

Ventilator-Associated PneumoniaConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicinePulmonology

Heart Failure: Comparing Spironolactone and Eplerenone

We are studying whether spironolactone or eplerenone is more effective in reducing the risk of death for patients with heart failure. This trial is for those receiving treatment in a heart failure clinic.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced NSCLC: Comparing Immune Treatments

We are studying two treatment strategies for patients with advanced non-small cell lung cancer to see which one works better. This trial also examines how these treatments affect the immune system and collects samples for future research.

Non-Small Cell Lung Cancer Stage IV>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

Prostate Cancer: Metastasis-Directed Therapy Study

We are investigating if a new treatment can improve survival for men with castration-refractory prostate cancer and a few progressive lesions. This study compares the new approach to standard care to see which is more effective.

Oligoprogressive Metastatic Castration-Refractory Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

GliomaEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics